Federal Supply Schedule 36F79723D0160
Award Date 7/15/23
Last Date to Order 6/30/24
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed Similar IDVs
- The Department of Veterans Affairs (VA) awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products to Provention Bio Inc., a biopharmaceutical company. This FSS contract, awarded by the VA's VISN 12 in July 2023, allows the VA to procure Provention Bio's pharmaceutical products, including TZIELD, to support VA healthcare programs serving veterans. Additionally, the VA National Acquisition Center awarded...
- The National Acquisition Center, a civilian agency within the Department of Veterans Affairs, awarded a single-award Blanket Purchase Agreement (BPA) to Provention Bio Inc. to provide the pharmaceutical product TZIELD. The $5 million BPA has a period of performance through June 2024 and is one of two BPAs awarded against Provention Bio's existing $5 million Federal Supply Schedule 65 I B contract, which was initially awarded in July 2023 for a 5-year term. An additional $1.44 million BPA was...
- This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Provention Bio Inc., a biopharmaceutical company, to provide the drug TZIELD. The single-award BPA has a ceiling value of $1,444,167.20 and a period of performance from January 2023 through July 2023. This BPA was issued against Provention Bio's 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals and...
- The Federal Supply Schedule (FSS) contract and Blanket Purchase Agreement (BPA) awarded to Bluebird Bio, Inc. by the U.S. Department of Veterans Affairs (VA) demonstrate the agency's interest in leveraging the company's gene therapies and hematology products to address the medical needs of the veteran population. The first IDV is a multiple-award, Schedule 65 IB FSS contract with a potential value of $300,000, which allows the VA's Veterans Integrated Service Network 12 to procure drugs,...
- The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022. A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the neuromyelitis...
- Novartis Pharmaceuticals Corporation holds a Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs with a ceiling value of $5.4 billion, awarded by Veterans Integrated Service Network 12 on September 1, 2020, with an ultimate completion date of August 31, 2026. This multiple-award indefinite delivery vehicle provides the Department of Veterans Affairs with access to a comprehensive portfolio of pharmaceutical products, including advanced cancer therapies and specialized...
- Proficient RX LP has been awarded a multiple-award Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs (FSS-61-IB) master schedule by the Veterans Integrated Service Network (VISN) 12, a civilian agency within the Department of Veterans Affairs. The contract, effective February 1, 2024, with an ultimate completion date of January 31, 2029, carries a ceiling value of $225,000.00 and establishes a vehicle for the supply of drugs, pharmaceuticals, and hematology-related...
- This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Profounda Inc., a self-certified small disadvantaged business, on July 1, 2020. The single-award BPA, valued at $1,127,000, establishes consignment terms for Profounda's Impavido/Miltefosine product through June 30, 2024. Impavido/Miltefosine is a specialty pharmaceutical used to treat leishmaniasis and other drug-resistant infections in veterans. Under this...
- The National Acquisition Center, a federal agency under the Department of Veterans Affairs, awarded a single-award Blanket Purchase Agreement (BPA) to Eiger Biopharmaceuticals, Inc. under the GSA Pharmaceuticals and Drugs schedule. This $204,359.25 BPA covers the purchase of Eiger's drug Zokinvy, used to treat Hutchinson-Gilford progeria syndrome, from January 2022 through January 2025. Eiger, a clinical-stage biopharmaceutical company, also holds a separate $205,000 single-award BPA from the VA...
- Takeda Pharmaceuticals America Inc. has been awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs National Acquisition Center with a ceiling value of $131.04 million for the period July 15, 2025, through July 14, 2026. This contract, issued under the General Services Administration Pharmaceuticals and Drugs Schedule (FSS-61-IB), encompasses procurement of nine specialized pharmaceutical products: CINRYZE, KALBITOR, TAKHZYRO, ELAPRASE, VPRIV, FIRAZYR, ADZYNMA,...
Name | Description | Awardee | Potential Value | AwardDate | LastDateToOrder | Updated At |
|---|---|---|---|---|---|---|
36F79723D0160-36E79723A0018 | Provention Bio Inc. | $5.0m | 8/15/23 | 6/30/24 | 6/27/24 |